Zoek een klinische studie of trial
Andere zoekoptie(s)
8 Resultaat/Resultaten
Aanwerving proef
= 
; Lopend onderzoek
= 
; Gefinancierd door een IRDiRC-lid = 
; Member of a ERN = 
Nationale klinische studie(s)
DUITSLAND
Nordrhein-Westfalen
MÜNSTER
A Pilot, open-label, single arm, multicentre study to explore safety, tolerability, pharmacokinetics and efficacy of intravenous multiple administrations of NI-0501, an Anti-interferon Gamma (Anti-IFNy) monoclonal antibody, in paediatric patients with Primary Haemophagocytic Lymphohistiocytosis which has reactivated (Phase II) - DE
Universitätsklinikum Münster
Klinik für Kinder- und Jugendmedizin - Pädiatrische Hämatologie und Onkologie
ITALIË
LOMBARDIA
MONZA
A Pilot, Open-label, Single Arm, Multicentre Study to Explore Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (Anti-IFNgamma) Monoclonal Antibody, in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis- IT
ASST Monza - Ospedale San Gerardo
Centro Ricerca "M.Tettamanti"
ITALIË
TOSCANA
FIRENZE
A Pilot, Open-label, Single Arm, Multicentre Study to Explore Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (Anti-IFNgamma) Monoclonal Antibody, in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis- IT
Azienda Ospedaliera Universitaria Anna Meyer
D.A.I. Oncoematologia
OOSTENRIJK
WIEN
WIEN
A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody (Phase II) - AT
St. Anna Kinderspital
Zentrum für Kinder- und Jugendheilkunde
SPANJE
Cataluña
ESPLUGUES DE LLOBREGAT
A multicentre study for the long-term follow-up of HLH patients who received treatment with NI-0501, an anti-interferon gamma monoclonal antibody (Phase II) - ES
Hospital Sant Joan de Déu Barcelona
Servicio de Alergia e Inmunología clínica
USA
California
WESTLAKE VILLAGE
Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric Subjects with Primary Immunodeficiency Diseases -GB
Baxalta US, Inc.
Multinationale klinische studie(s)
ZWITSERLAND
Suisse Romande
PLAN-LES-OUATES
FIGHT-HLH: First Targeted Therapy to FIGHT Hemophagocytic Lymphohistiocytosis (HLH): A novel approach to HLH
NovImmune SA
ZWITSERLAND
Suisse Romande
PLAN-LES-OUATES